MX2008007697A - Nanocumulos para la distribucion de farmacos. - Google Patents

Nanocumulos para la distribucion de farmacos.

Info

Publication number
MX2008007697A
MX2008007697A MX2008007697A MX2008007697A MX2008007697A MX 2008007697 A MX2008007697 A MX 2008007697A MX 2008007697 A MX2008007697 A MX 2008007697A MX 2008007697 A MX2008007697 A MX 2008007697A MX 2008007697 A MX2008007697 A MX 2008007697A
Authority
MX
Mexico
Prior art keywords
nano
nanoclusters
therapeutics
delivery
particles
Prior art date
Application number
MX2008007697A
Other languages
English (en)
Spanish (es)
Inventor
Cory J Berkland
Lianjun Shi
Original Assignee
Univ Kansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kansas filed Critical Univ Kansas
Publication of MX2008007697A publication Critical patent/MX2008007697A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2991—Coated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2991—Coated
    • Y10T428/2998—Coated including synthetic resin or polymer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nanotechnology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Composite Materials (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Materials Engineering (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2008007697A 2005-12-16 2006-12-14 Nanocumulos para la distribucion de farmacos. MX2008007697A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75117205P 2005-12-16 2005-12-16
PCT/US2006/062118 WO2007076295A2 (en) 2005-12-16 2006-12-14 Nanoclusters for delivery of therapeutics

Publications (1)

Publication Number Publication Date
MX2008007697A true MX2008007697A (es) 2008-09-26

Family

ID=37808148

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008007697A MX2008007697A (es) 2005-12-16 2006-12-14 Nanocumulos para la distribucion de farmacos.

Country Status (11)

Country Link
US (3) US7651770B2 (enExample)
EP (1) EP1968550A2 (enExample)
JP (1) JP2009519975A (enExample)
CN (1) CN101370479A (enExample)
AU (1) AU2006330627A1 (enExample)
BR (1) BRPI0619938A2 (enExample)
CA (1) CA2633380A1 (enExample)
IL (1) IL192159A0 (enExample)
MX (1) MX2008007697A (enExample)
WO (1) WO2007076295A2 (enExample)
ZA (1) ZA200805918B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040096515A1 (en) * 2001-12-07 2004-05-20 Bausch Andreas R. Methods and compositions for encapsulating active agents
WO2006096571A2 (en) * 2005-03-04 2006-09-14 President And Fellows Of Harvard College Method and apparatus for forming multiple emulsions
US8906392B2 (en) * 2005-12-16 2014-12-09 University Of Kansas Nanocluster compositions and methods
WO2010009146A1 (en) * 2008-07-15 2010-01-21 University Of Kansas Nanoclusters for delivery of poorly water soluble drug nanoparticles
US7993749B2 (en) * 2005-12-16 2011-08-09 University Of Kansas Nanoparticles comprising a nanoparticle template and a polymer shell having an amide side chain, and method of making thereof
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
ES2425969T3 (es) * 2007-04-27 2013-10-18 Kyushu University, National University Corporation Agente para el tratamiento de enfermedades pulmonares
EP2170283B1 (en) 2007-06-22 2019-01-09 Board of Regents, The University of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
US20090047318A1 (en) * 2007-08-16 2009-02-19 Abbott Cardiovascular Systems Inc. Nanoparticle-coated medical devices and formulations for treating vascular disease
US20090123509A1 (en) * 2007-11-08 2009-05-14 Cory Berkland Biodegradable Colloidal Gels as Moldable Tissue Engineering Scaffolds
WO2009086067A2 (en) * 2007-12-28 2009-07-09 Boston Scientific Scimed, Inc. Particles for injection and processes fo forming the same
JP5351054B2 (ja) * 2008-05-09 2013-11-27 アークレイ株式会社 不溶性担体粒子の製造方法、不溶性担体粒子、測定試薬、検体分析用具および免疫比濁法
JP5841708B2 (ja) * 2008-07-01 2016-01-13 日東電工株式会社 表面被覆微粒子の医薬組成物
JP5711138B2 (ja) 2008-11-16 2015-04-30 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 高濃度の低粘度懸濁液
US8053744B2 (en) * 2009-04-13 2011-11-08 Src, Inc. Location analysis using nucleic acid-labeled tags
US10952965B2 (en) * 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
WO2011028764A2 (en) 2009-09-02 2011-03-10 President And Fellows Of Harvard College Multiple emulsions created using jetting and other techniques
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
US10525152B2 (en) 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
KR101878749B1 (ko) * 2010-03-05 2018-07-17 삼성전자주식회사 표적 세포의 분리 방법 및 키트
US20110229545A1 (en) * 2010-03-17 2011-09-22 President And Fellows Of Harvard College Melt emulsification
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
US8703493B2 (en) 2010-06-15 2014-04-22 Src, Inc. Location analysis using fire retardant-protected nucleic acid-labeled tags
US20120016217A1 (en) * 2010-07-15 2012-01-19 Indian Institute Of Technology Bombay Biosensor for health monitoring and uses thereof
WO2012018628A1 (en) 2010-07-26 2012-02-09 Board Of Regents, The University Of Texas System Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine
US8716027B2 (en) 2010-08-03 2014-05-06 Src, Inc. Nucleic acid-labeled tags associated with odorant
JP6343147B2 (ja) * 2010-08-30 2018-06-13 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 狭窄病変および血栓溶解療法のための剪断による制御放出
US20120230913A1 (en) * 2011-03-10 2012-09-13 Board Of Regents, The University Of Texas System Protein nanoparticle dispersions
BR112013029729A2 (pt) 2011-05-23 2017-01-24 Basf Se controle de emulsões, incluindo emulsões múltiplas
WO2012162555A2 (en) * 2011-05-24 2012-11-29 The Regents Of The University Of California Heparin nanoclusters
PH12013502474A1 (en) * 2011-06-02 2014-02-10 Consejo Superior De Investig CientaFicas C S I C Use of raman markers for authenticating security documents
US20140220350A1 (en) 2011-07-06 2014-08-07 President And Fellows Of Harvard College Multiple emulsions and techniques for the formation of multiple emulsions
CA2869849A1 (en) * 2012-04-13 2013-10-17 Glaxosmithkline Intellectual Property Development Limited Aggregate particles comprising nanoparticulate drug particles of umeclidinium bromide, vilanterol trifenatate and fluticasone furoate
JP2015520194A (ja) * 2012-06-07 2015-07-16 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 薬物標的指向化のためのナノ療法
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9974850B2 (en) 2013-01-25 2018-05-22 Board Of Regents, The University Of Texas System Immunogenic compositions and uses thereof
JP2016518388A (ja) 2013-04-30 2016-06-23 オティトピック インク． 乾燥粉末配合および使用方法
IL318076A (en) 2013-08-13 2025-02-01 Univ Northwestern Peptide-conjugated particles
MD20160061A2 (ro) * 2013-11-13 2016-10-31 Tillotts Pharma Ag Sistem de livrare a medicamentului compus din particule multiple
CN104550936B (zh) * 2014-12-31 2017-05-31 中国科学院合肥物质科学研究院 纳米颗粒组装的胶状体材料及其制备方法
US11059014B2 (en) 2015-08-17 2021-07-13 Japan Science And Technology Agency Nanocluster liquid dispersion, nanocluster film, nanocluster solid dispersion, method for producing nanocluster liquid dispersion, and device for producing nanocluster liquid dispersion
US20170128424A1 (en) * 2015-11-11 2017-05-11 Qrono, Inc. Sustained release pharmaceutical compositions and methods of use
KR101803283B1 (ko) * 2016-12-30 2017-12-01 (주)아모레퍼시픽 항노화용 또는 주름개선용 화장료 조성물
US11446391B2 (en) 2017-07-06 2022-09-20 The Trustees Of The University Of Pennsylvania Amphiphilic dye-coated inorganic nanoparticle clusters
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
KR102507987B1 (ko) 2017-09-22 2023-03-21 벡추라 인코포레이티드 스테아르산마그네슘을 갖는 건조 분말 조성물
US11819488B2 (en) 2018-02-23 2023-11-21 Rhnanopharma Nanosuspensions of salsalate and methods of using the same
US20220202715A1 (en) * 2019-04-02 2022-06-30 Xichuan Seawagen Company Limited Dynamic clusters of atom particles activated in extracellular fluid
CA3194232A1 (en) 2020-09-29 2022-04-07 Daniel Beard Stroke treatment

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09913A (ja) * 1995-06-14 1997-01-07 Res Dev Corp Of Japan コロイド粒子クラスターとその形成方法
US5814370A (en) * 1996-06-11 1998-09-29 Sandia Corporation Encapsulation of nanoclusters in dried gel materials via an inverse micelle/sol gel synthesis
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6656568B1 (en) * 1999-05-28 2003-12-02 The Regents Of The University Of Colorado Ordered arrays of nanoclusters
GB9929919D0 (en) * 1999-12-17 2000-02-09 Hannah Research Inst The Calcium phosphate nanoclusters and their applications
WO2001091808A2 (en) * 2000-06-01 2001-12-06 The Board Of Regents For Oklahoma State University Bioconjugates of nanoparticles as radiopharmaceuticals
DE60140625D1 (de) * 2000-08-15 2010-01-07 Univ Illinois Verfahren zur herstellung von mikropartikeln
US20030138490A1 (en) * 2001-09-08 2003-07-24 Zhibing Hu Synthesis and uses of polymer gel nanoparticle networks
WO2003062372A2 (en) * 2001-10-02 2003-07-31 The Regents Of The University Of California Nanoparticle assembled hollow spheres
US20030062372A1 (en) * 2001-10-02 2003-04-03 Metso Minerals (Trelleborg) Ab Wear-resistant lining element and wear lining made thereof
US6562403B2 (en) * 2001-10-15 2003-05-13 Kansas State University Research Foundation Synthesis of substantially monodispersed colloids
EP1470563A2 (en) * 2002-01-25 2004-10-27 Konarka Technologies, Inc. Photovoltaic cell components and materials
EP1480691A4 (en) * 2002-03-05 2007-11-28 Univ State Cleveland AGGLOMERATED PARTICLES FOR THE DISPOSAL OF A MEDICINAL PRODUCT IN AEROSOL FORM
US20060078540A1 (en) 2002-03-18 2006-04-13 Warren William L Dendritic cell nodes
JP4142318B2 (ja) * 2002-03-20 2008-09-03 株式会社ホソカワ粉体技術研究所 薬物含有複合粒子の製造方法
DE60326597D1 (de) * 2002-06-05 2009-04-23 Univ Florida Ophthalmisches arzneimittelabgabesystem
JP2006500387A (ja) * 2002-08-15 2006-01-05 雲清 劉 固形ナノ医薬およびその調製方法
US7811605B2 (en) * 2002-11-06 2010-10-12 Uluru Inc. Method of formation of shape-retentive aggregates of gel particles and their uses
US6928201B2 (en) * 2002-11-15 2005-08-09 Sunrise Telecom Incorporated Method and apparatus for providing controllable second-order polarization mode dispersion
CA2523413A1 (en) 2003-04-25 2004-11-11 The Penn State Research Foundation Method and system for systemic delivery of growth arresting, lipid-derived bioactive compounds
AU2004263094A1 (en) * 2003-07-09 2005-02-17 Vaxdesign Corporation Programmed immune responses using a vaccination node
CA2435632A1 (en) * 2003-07-21 2005-01-21 Warren Hugh Finlay Formulation of powder containing nanoparticles for aerosol delivery to the lung
US20070265357A1 (en) * 2003-12-19 2007-11-15 Thomson Licensing Systems for Preparing Fine Articles and Other Substances
EP1696965B1 (en) * 2003-12-22 2014-12-10 Bracco Suisse SA Assembly of gas-filled microvesicle with active component for contrast imaging
US7610074B2 (en) * 2004-01-08 2009-10-27 The Board Of Trustees Of The University Of Illinois Multi-functional plasmon-resonant contrast agents for optical coherence tomography

Also Published As

Publication number Publication date
EP1968550A2 (en) 2008-09-17
US20090053316A1 (en) 2009-02-26
WO2007076295A3 (en) 2007-11-29
BRPI0619938A2 (pt) 2011-10-25
IL192159A0 (en) 2008-12-29
JP2009519975A (ja) 2009-05-21
US20070172653A1 (en) 2007-07-26
US20090081295A1 (en) 2009-03-26
CA2633380A1 (en) 2007-07-05
CN101370479A (zh) 2009-02-18
US7651770B2 (en) 2010-01-26
WO2007076295A2 (en) 2007-07-05
AU2006330627A1 (en) 2007-07-05
ZA200805918B (en) 2009-05-27

Similar Documents

Publication Publication Date Title
MX2008007697A (es) Nanocumulos para la distribucion de farmacos.
WO2007133731A3 (en) Creatine-ligand compounds and methods of use thereof
MX2009003098A (es) Compuestos de tiofen pirazolopirimidina.
UA108832C2 (uk) Комбінації кон'югата анти-her2-антитіло-лікарський засіб і хіміотерапевтичних засобів і способи застосування
WO2008054208A3 (en) Use of nutritional compositions for preventing disorders
TW200719913A (en) Anti-madcam antibody compositions
MX2009011359A (es) Derivados de pirimidinona y sus metodos de uso.
UA103614C2 (uk) Лікарський засіб, що містить комбінацію інгібітора кінази та анти-гліпікан 3-антитіла, для лікування раку печінки
NZ617196A (en) Activin-actrii antagonists and uses for increasing red blood cell levels
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
MY176679A (en) Use of nutritional compositions for preventing disorders
UA93201C2 (ru) АНТИТЕЛО, KOTOPOE НЕЙТРАЛИЗУЕТ ЧЕЛОВЕЧЕСКИЙ TGF-b1
MY157365A (en) Chemical compounds and uses
EA201071421A1 (ru) Анти-flt3 антитела
GEP20125565B (en) Lactam compounds and their pharmaceutical use
MX2011000255A (es) Combinacion de un antagonista a c-met y un compuesto aminoheteroarilo, para el tratamiento de cancer.
CL2007002705A1 (es) Composicion farmaceutica oftalmica autopreservada que comprende 0,04 a 0,9 mm de iones zinc donde la concentracion de aniones tamponantes es menor que 15 mm.
WO2008030273A3 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2007123723A3 (en) Diagnosis and treatment of alzheimer's disease
WO2008063768A3 (en) Compositions and methods for treating metabolic diseases
MX2009008135A (es) Uso de histidinato de cromo para tratamiento de alteraciones cardiometabolicas.
MX2011010919A (es) Antagonistas del receptor 2 de citocina quimioatrayente de 4-azetidinil-1-heteroaril-ciclohexano.
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
MY162440A (en) 2,5-disubstituted arylsulfonamide ccr3 antagonists
PL1693064T3 (pl) Leczenie utraty wagi za pomocą S. boulardii u pacjentów cierpiących na choroby zapalne jelit

Legal Events

Date Code Title Description
FG Grant or registration